An interesting article ....
https://www.healio.com/news/gastroe...oms-more-frequently-than-noninfected-controls
Patients with COVID-19 experience GI symptoms more frequently than noninfected controls
In a prospective study, researchers analyzed data from 883 hospitalized patients to investigate the prevalence of GI symptoms and post-COVID-19 disorders of gut-brain interaction (DGBI). They enrolled 269 patients with SARS-CoV-2 infection (mean age, 49.9 years; 59.9% men) and 269 controls (mean age, 50.9 years; 62.1% men), who were assessed for GI symptoms, anxiety and depression at admission and 1, 6 and 12 months after hospitalization. Secondary study endpoints included assessment of post-infection DGBI predictive factors.
RWE for 2nd MSB COVID-19 ARDS P3 Trial, page-869
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.0¢ |
Change
-0.005(0.54%) |
Mkt cap ! $1.050B | |||
| Open | High | Low | Value | Volume |
| 92.0¢ | 92.5¢ | 91.5¢ | $1.133M | 1.233M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 151980 | 91.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 92.0¢ | 29989 | 2 |
View Market Depth
| Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |